Signalife, Inc.
Medical Devices & Tech
531 South Main Street, Suite 301
Greenville, SC 29601 USA
phone: 864-233-2300
fax: 864-233-2100
Symbol SGN
Exchange AMEX
Founded 1998
Employees
www.signalife.com
Research Sector Medical Devices & Tech
Summary Description
Continuous biomedical signal monitoring.
Management
Pamela Bunes, President & CEO; Budimir S. Drakulic, PhD, Chief Technology Officer & Chief Scientist
Ownership
Financials Mkt Cap :3


* numbers in thousands

Recent Results
For the second quarter ended June 2006, Signalife recognized $500,000 of the $2 million Rubbermaid paid for the first year of its distribution agreement. The rest of payment will be recognized over the course of the year. Net loss for the quarter was $2.8 million, essentially flat over Q2 2005.
 
Keywords
electrocardiograph, ecg, patient, monitoring, ambulatory, diagnostic, ambulance, ambulatory

Comment | Printable Version | Sept. 01, 2008
If you work for Signalife, Inc. and want to update this profile, click here

Description
Signalife is focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Products / Services
Fidelity 100 Monitor System is an integrated system which collects, processes and amplifies ECG signals and transmits them to a PC provided with the system.
Technology / Differentiation
Signalife's heart monitor systems collect physiological data for electrocardiogram (ECG) test in order to detect cardiovascular disease. The Fidelity 100 allows a patient's heart to be continuously monitored over a period of 24 to 48 hours in a variety of settings - both ambulatory (moving) and non-ambulatory (stationary) - such as hospitals, surgeries, doctor's offices and sports medicine clinics. Signalife's technology compresses and reduces noise prior to amplifying the ECG signals. The signals are wirelessly transmitted to a near by PC and displayed on the monitor for analysis by a cardiologist.
Market / Customers
Signalife estimates that cardiovascular disease accounts for 40% of all hospital revenue. Over 500,000 Americans survive heart attacks each year and need to be diagnostically monitored. 280,000 patients have various heart devices implanted.
Competitors / Substitutes / Alternatives
Cardiac Science Corp, GE Healthcare, Raytel Medical Corp
Strategy
Fidelity 100 will be marketed in the U.S. by Rubermaid, Inc. Rubbermaid will absorb expenses for assembling a national sales force and advertising activities. The initial terms of the agreement is for one year but can be renewed by Rubbermaid on an annual basis. The agreement may also be extended to international markets.
Status
In May, Signalife announced the development of the prototype of its next key product , the Holter Monitor. The monitor operates using similar technology to the Fidelity 100, but is focused on detecting arrhythmias.


2008-09-07-576